Article
Genomic relationship between polyendocrine metabolic ovarian syndrome and bipolar disorder.
European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology - 1 Nov 2026
Jaholkowski Piotr, Tesfaye Markos, Fominykh Vera, Parekh Pravesh, Wiström Erik D, Parker Nadine, Koch Elise, Bauer Anna E, Trzaskoma Pawel, Rokicki Jaroslav, Bahrami Shahram, Rahman Zillur, Frei Oleksandr, Djurovic Srdjan, Dale Anders M, Shadrin Alexey A, O'Connell Kevin S, Andreassen Ole A
Abstract excerpt
Women with bipolar disorder (BIP) have a higher risk of developing polyendocrine metabolic ovarian syndrome (PMOS). Shared genetic architecture may underlie this comorbidity. Valproate, a mood-stabilizer commonly used to treat BIP, increases the risk of PMOS. Still, the mechanism underlying PMOS in BIP remains unknown. Here, we aimed to identify genetic variants shared between BIP and PMOS, as well as their...
Read the complete abstract on PubMedTopics
- Female
- Humans
- Bipolar Disorder
- Genome-Wide Association Study
